Bold Brain Capital

Bold Brain Capital is a venture capital firm that specializes in early-stage investments within the life sciences sector, with a particular focus on companies developing AI-enabled technologies for healthcare. The firm aims to advance the integration of artificial intelligence into medical practices, believing that physician involvement is crucial for creating AI solutions that genuinely enhance patient care, improve physician workflows, and optimize outcomes. Bold Brain Capital operates as a network that connects medical professionals with groundbreaking AI startups, offering opportunities for physicians to invest alongside the firm's team and engage with portfolio companies through consulting or board roles.

Founded in 2018, Bold Brain Capital was established by its partners with the vision of creating a platform for physicians to actively participate in the evolution of AI-driven healthcare companies. The firm addresses a gap in the market by providing individual physician investors access to venture capital opportunities in early-stage life sciences companies that would typically be inaccessible. This model benefits both physicians, who gain investment and engagement opportunities, and growth-stage AI companies, which receive capital, talent, and networking advantages from a network of medical professionals who are also end-users of their products.

The firm's portfolio includes companies like Vista AI, which recently secured significant Series B funding for its automated MRI scanning technology, and Elucid, known for its coronary plaque analysis software. These investments highlight Bold Brain Capital's commitment to supporting innovative AI solutions that have the potential to transform medical imaging and diagnostics. The firm actively seeks startups typically in Seed through Series C funding rounds that are focused on transformational AI-enabled technologies.

The General Partners at Bold Brain Capital bring over 100 years of combined experience from clinical practice, venture capital, and operating businesses within the life sciences industry. This extensive expertise is complemented by a network of over 1000 doctors who invest as Limited Partners. Key team members include Managing Partners Mike Thomas, Tom Deur, Robin Prasad, and Will Anlyan, who collectively drive the firm's investment strategy and foster its unique physician-centric network.